Search results
Dupixent set for FDA review in adolescent chronic inflammatory sinus disease
Pharmaceutical Technology via Yahoo Finance· 2 days agoCRSwNP is a chronic inflammatory disease that can lead to breathing difficulties, nasal congestion,...
Sanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag
Zacks via Yahoo Finance· 2 days agoSanofi (SNY) and Regeneron's (REGN) Dupixent is poised to be the first medicine for adolescents with...
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with...
Benzinga· 2 days agoFood and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) as an add-on maintenance ...